Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors



Status:Recruiting
Conditions:Colorectal Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/8/2019
Start Date:September 2013
End Date:June 2021
Contact:Jane Zorzi
Email:jzorzi1@jhmi.edu
Phone:410-614-5818

Use our guide to learn which trials are right for you!

This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T
cells) is effective (anti-tumor activity) and safe in three different patient populations.
These include: 1. patients with MSI positive colon cancer, 2. patients with MSI negative
colon cancer 3. patients with other MSI positive cancers, and 4. patients with MSI negative
cancer with a mutator phenotype.


Inclusion Criteria:

- Arm 1 only: Patients with microsatellite instability (MSI) positive colorectal cancer

- Arm 2 only: Patients with MSI negative colorectal cancer

- Arm 3 only: Patients with MSI positive non-colorectal cancer

- Arm 4 only: patients with hypermutated MSI negative cancer

- Have measurable disease

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1

- Adequate organ function as defined by study-specified laboratory tests

- Must use acceptable form of birth control through the study and for 28 days after
final dose of study drug

- Signed informed consent form

- Willing and able to comply with study procedures

- Agree to have a biopsy of their cancer

- Patients with colon cancer must have received at least two prior cancer therapy
regimens.

- Patients with other cancer types must have received at least one prior cancer therapy

- Progressive disease

Exclusion Criteria:

- Patients with uncontrolled intercurrent illness, including but not limited to ongoing
or active infection, systematic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia or psychiatric condition that would limit compliance with study
requirements.

- Patients who have had chemotherapy or biological cancer therapy within 2 weeks prior
to the first dose of study drug

- Patients who have had radiation within 2 weeks prior to the first dose of study drug

- Patients who have undergone major surgery within 4 weeks of dosing of investigational
agent

- Patients who have received another investigational product or investigational device
within 4 weeks prior to receiving study drug

- Patients who have received any of the following concomitant therapy: Interleukin-2
(IL-2), interferon, or other non-study immunotherapy regimens, immunosuppressive
agents, other investigational therapies or chronic use of systemic corticosteroids
within one week prior to first dose of study drug

- Patients who have received a live vaccine within 4 weeks prior to or after any dose of
MK-3475 (exception: inactivated flu vaccines)

- Patients who have received growth factors, including but not limited to
granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony
stimulating factor (GM-CSF), erythropoietin, etc. within 2 weeks of study drug
administration

- Patient who have had prior treatment with anti-PD-1 (anti-programmed cell death
protein 1), anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, or anti-CTLA-4
antibodies

- Patients with history of any autoimmune disease:inflammatory bowel disease, (including
ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive
sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis,
central nervous system (CNS) or motor neuropathy considered to be of autoimmune
origin.

- Patients who have known history of infection with HIV, hepatitis B, or hepatitis C

- Patients with evidence of interstitial lung disease

- Systemically active steroid use

- Patients on home oxygen

- Patients with oxygen saturation of <92% on room air by pulse oximetry

- Pregnant or lactating

- Conditions, including alcohol or drug dependence, or intercurrent illness that would
affect the patient's ability to comply with study visits and procedures

- Patient with known active central nervous system metastases and/or carcinomatous
meningitis.

- Patients with primary brain tumors.

- Requires any other form of systemic or localized antineoplastic therapy while on study

- Has any tissue or organ allograft

- Patients with history of allogeneic hematopoeitic stem cell transplant
We found this trial at
8
sites
Bethesda, Maryland 20892
Principal Investigator: Tim F Greten, MD
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Baltimore, Maryland 21231
410-955-6190
Principal Investigator: Dung Le, MD
Phone: 410-614-3644
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Todd Crocenzi, MD
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Principal Investigator: John Hays, MD
Phone: 614-293-6529
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Luis Diaz
Phone: 646-888-4444
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Kim R Binder, MD
Phone: 215-360-0735
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
5150 Centre Ave
Pittsburgh, Pennsylvania 15232
(412) 647-2811
Principal Investigator: James Lee, MD; PhD
University of Pittsburgh Cancer Institute Founded in 1985, the University of Pittsburgh Cancer Institute (UPCI)...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Principal Investigator: George Fisher, MD
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials